Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads ...

Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to Instagram on Wednesday and revealed that her mom was diagnosed with Stage 1 HER2 ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

US FDA clears Iksuda Therapeutics’ IND application for IKS014: New Castle, England Wednesday, July 2, 2025, 15:00 Hrs [IST] Iksuda Therapeutics, a clinical stage and UK-based bi ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.